Why Revolution Medicines, Inc.’s (RVMD) Stock Is Up 5.01%
As of Thursday, July 23, Revolution Medicines, Inc.’s RVMD share price has surged by 5.01%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Commentary & Analysis
Why Revolution Medicines, Inc.’s (RVMD) Stock Is Up 6.57%
As of Thursday, June 25, Revolution Medicines, Inc.’s RVMD share price has surged by 6.57%, which has investors questioning if this is right time to sell.Michael Rose
Why Revolution Medicines, Inc.’s (RVMD) Stock Is Down 5.15%
As of Wednesday, June 10, Revolution Medicines, Inc.’s RVMD share price has dipped by 5.15%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Revolution Medicines, Inc.’s (RVMD) Stock Is Down 5.84%
As of Tuesday, June 02, Revolution Medicines, Inc.’s RVMD share price has dipped by 5.84%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Revolution Medicines, Inc.’s (RVMD) Stock Is Down 5.01%
As of Thursday, May 07, Revolution Medicines, Inc.’s RVMD share price has dipped by 5.01%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | RVMD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $39,868.2 | $252.6 | 92% |
|
| Shares Out (Mil) | 198.1 | 52.3 | 76% |
|
| Institutional Ownership | 97.5% | 92.1% | 74% |
|
| Float (Mil) | 194.1 | 40.2 | 74% |
|
| Beta | 1.41 | 0.95 | 80% |
|
| Avg Daily Volume (000s) | 1,872 | 455 | 81% |
|
| Price Change (52-week) |
406.6% | 52.9% | 99% |
|
| Growth | RVMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (59.9%) | (9.9%) | 5% |
|
| EPS (5yr) | (24.2%) | 16.0% | 11 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (20.3%) | (15.6%) | 32% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 16 | 19 | 17 | |
| Current EPS | ($2.057) | ($8.068) | ($5.801) | |
| Month Ago EPS | ($2.029) | ($8.049) | ($5.811) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | ($1.900) | ($7.483) | ($5.240) | |
| Year/Year Chg | (10.2%) | 35.6% | (53.3%) | |
| Financials | RVMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($1,372) | ($43) | 1% |
|
| EPS (TTM) | ($7.121) | ($1.600) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($1,058) | ($31) | 1% |
|
| Net Cash Flow (TTM) (Mil) | $109 | $5 | 78% |
|
| Long-Term Debt (Q1) (Mil) | $421 | $5 | 57% |
|
| Enterprise Value (Q1) (Mil) | $28,678 | $180 | 87% |
|
| Valuation | RVMD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 25.04 | 2.56 | 97% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | RVMD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (59.4%) | (49.8%) | 10% |
|
| ROE | (76.7%) | (55.5%) | 12% |
|
| Liabilities to Assets | 33.4% | 30.3% | 24% |
|
| F-Score | 1 | 3 | 1% |
|
Revolution Medicines, Inc. did not pass any screens on 7/31/2026.
